Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan A Fletcher

Showing results (181-190 of 205) with videos related to

Pageof 21
Sort By:
Nature Genetics|May 6, 2014
A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutationsShinji Kohsaka, Neerav Shukla, Nabahet Ameur, et al.
Oncotarget|February 26, 2014
Cytotoxic effects of 15d-PGJ2 against osteosarcoma through ROS-mediated AKT and cell cycle inhibitionChueh-Chuan Yen, Chung-Der Hsiao, Wei-Ming Chen, et al.
International Journal of Oncology|September 3, 2009
Identification of chromosomal aberrations associated with disease progression and a novel 3q13.31 deletion involving LSAMP gene in osteosarcomaChueh-Chuan Yen, Wei-Ming Chen, Tain-Hsiung Chen, et al.
Blood|March 20, 2010
Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutantsEllen Weisberg, Hwan Geun Choi, Arghya Ray, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 28, 2004
PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorderJing Chen, Daniel J Deangelo, Jeffery L Kutok, et al.
Cancers|September 27, 2025
Future Directions and Priorities for Cellular Therapy in Sarcoma: A Report from the Strategic Advances in Sarcoma Science Cell Therapy BreakoutJacqueline Oliva-Ramirez, David Milewski, Lauren Banks, et al.
Nature Genetics|May 6, 2014
Dystrophin is a tumor suppressor in human cancers with myogenic programsYuexiang Wang, Adrian Marino-Enriquez, Richard R Bennett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2003
Soft tissue sarcomas of adults: state of the translational scienceErnest C Borden, Laurence H Baker, Robert S Bell, et al.
The Journal of Experimental Medicine|June 18, 2021
E3 ligase MKRN3 is a tumor suppressor regulating PABPC1 ubiquitination in non-small cell lung cancerKe Li, Xufen Zheng, Hua Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2015
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT InhibitionRichard D Carvajal, Donald P Lawrence, Jeffrey S Weber, et al.
Pageof 21

Showing results (181-190 of 205) with videos related to

Sort By:
Pageof 21
Nature Genetics|May 6, 2014
A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutationsShinji Kohsaka, Neerav Shukla, Nabahet Ameur, et al.
Oncotarget|February 26, 2014
Cytotoxic effects of 15d-PGJ2 against osteosarcoma through ROS-mediated AKT and cell cycle inhibitionChueh-Chuan Yen, Chung-Der Hsiao, Wei-Ming Chen, et al.
International Journal of Oncology|September 3, 2009
Identification of chromosomal aberrations associated with disease progression and a novel 3q13.31 deletion involving LSAMP gene in osteosarcomaChueh-Chuan Yen, Wei-Ming Chen, Tain-Hsiung Chen, et al.
Blood|March 20, 2010
Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutantsEllen Weisberg, Hwan Geun Choi, Arghya Ray, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 28, 2004
PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorderJing Chen, Daniel J Deangelo, Jeffery L Kutok, et al.
Cancers|September 27, 2025
Future Directions and Priorities for Cellular Therapy in Sarcoma: A Report from the Strategic Advances in Sarcoma Science Cell Therapy BreakoutJacqueline Oliva-Ramirez, David Milewski, Lauren Banks, et al.
Nature Genetics|May 6, 2014
Dystrophin is a tumor suppressor in human cancers with myogenic programsYuexiang Wang, Adrian Marino-Enriquez, Richard R Bennett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2003
Soft tissue sarcomas of adults: state of the translational scienceErnest C Borden, Laurence H Baker, Robert S Bell, et al.
The Journal of Experimental Medicine|June 18, 2021
E3 ligase MKRN3 is a tumor suppressor regulating PABPC1 ubiquitination in non-small cell lung cancerKe Li, Xufen Zheng, Hua Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2015
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT InhibitionRichard D Carvajal, Donald P Lawrence, Jeffrey S Weber, et al.
Pageof 21